WallStreetZenWallStreetZen

NYSEMKT: MTNB
Matinas Biopharma Holdings Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MTNB past revenue growth

How has MTNB's revenue growth performed historically?
Company
98.43%
Industry
112.01%
Market
13.97%
MTNB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MTNB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MTNB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MTNB earnings and revenue history

Current Revenue
$4.3M
Current Earnings
-$21.3M
Current Profit Margin
-496.3%

MTNB Return on Equity

Current Company
-70.7%
Current Industry
15.6%
Current Market
-9.5%
MTNB's Return on Equity (-70.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MTNB announces earnings.

MTNB Return on Assets

Current Company
-57.9%
Current Industry
2.2%
MTNB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MTNB Return on Capital Employed

Current Company
-80.05%
Current Industry
17.7%
MTNB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MTNB vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MTNB$4.28M-$20.34M-$21.26M+98.43%N/A
CNTB$0.00N/A-$83.71MN/AN/A
CLNN$718.00k-$34.12M-$40.39M+145.12%N/A
YSN/AN/AN/AN/AN/A
TSBXN/AN/AN/AN/AN/A
View Top Biotech Stocks

Matinas Biopharma Holdings Earnings & Revenue FAQ

What were MTNB's earnings last quarter?

On Invalid Date, Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q3 2023 earnings per share (EPS) of -$0.03, up 0% year over year. Total Matinas Biopharma Holdings earnings for the quarter were -$6.06 million. In the same quarter last year, Matinas Biopharma Holdings's earnings per share (EPS) was -$0.03.

If you're new to stock investing, here's how to buy Matinas Biopharma Holdings stock.

What was MTNB's earnings growth in the past year?

As of Q4 2023, Matinas Biopharma Holdings's earnings has grown year over year. Matinas Biopharma Holdings's earnings in the past year totalled -$21.26 million.

What was MTNB's revenue last quarter?

On Invalid Date, Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q3 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Matinas Biopharma Holdings's revenue was $1.06 million.

What was MTNB's revenue growth in the past year?

As of Q4 2023, Matinas Biopharma Holdings's revenue has grown 98.43% year over year. This is 13.58 percentage points lower than the US Biotechnology industry revenue growth rate of 112.01%. Matinas Biopharma Holdings's revenue in the past year totalled $4.28 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.